Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
RESEARCH TOOLSreports
BHC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$5.45 - C$13.74
Previous CloseN/A
Volume45.48K
Average Volume (3M)435.44K
Market Cap
$2.70B
Enterprise ValueC$35.33B
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$21.51B
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Jul 30, 2025EPS Estimate
1.36Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding369,512,500
10 Day Avg. Volume556,948
30 Day Avg. Volume435,438
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap13.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.16
Enterprise Value/Ebitda12.49
Forecast
1Y Price Target
$10.79Price Target Upside44.46% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Debt ManagementThe company has liquidity to address upcoming debt maturities, and debt restructuring is considered possible given the retained ownership of B+L.
Financial PerformanceBausch Health traded with strength, with its guidance exceeding consensus, showing a stronger than expected performance.
Shareholder ValueThe company has introduced the option of a buyback as part of its capital allocation strategy, which could be seen as a positive move for shareholder value.
Bears Say
Litigation UncertaintyBausch Health did not offer any updates on the timeline for the lawsuit regarding Norwich's generic Xifaxan, adding to the uncertainty.
Spin-off UncertaintyBausch Health Companies did not provide a meaningful update on the proposed spin-off of Bausch + Lomb, which could be affecting investor sentiment.
Tariff ChallengesThe company faces challenges with tariffs impacting its Solta business in China, where they are trying to mitigate these impacts with locally sourced inventories.
---
Options Prices
Currently, No data available
---
Ownership Overview
19.01% Insiders
3.97%
Mutual Funds
0.08% Other Institutional Investors
72.44% Public Companies and
Individual Investors
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$5.45 and its highest was C$13.74 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $2.70B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Jul 30, 2025 which is in 88 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Apr 30, 2025. The company reported C$0.947 earnings per share for the quarter, missing the consensus estimate of C$1.159 by -C$0.212.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$1.383 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 1.36.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 369,512,500 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$0.947 in its last earnings report, missing expectations of C$1.159. Following the earnings report the stock price went down -0.273%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in TSE:BHC
---
Bausch Health Companies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.79 (44.46% Upside)
$10.79 (44.46% Upside)
Blogger Sentiment
Bullish
TSE:BHC Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.42%
12-Months-Change
Fundamentals
Return on Equity
3.60%
Trailing 12-Months
Asset Growth
-3.02%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
---
BHC Company Deck
---
BHC Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Bausch Health demonstrated strong financial performance with growth in revenue and EBITDA, successful refinancing efforts, and legal victories. However, the company faces challenges with increased interest expenses and potential impacts from tariffs and trade measures.Read More>---
BHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
---
BHC Stock 12 Month Forecast
Average Price Target
C$10.79
▲(44.46% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Cronos Group
―
HLS Therapeutics Inc
―
---